VSTM — Verastem, Inc.

Verastem Oncology (VSTM) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Product Revenue: $17.5 million for Q4 2025; $30.9 million for the full year (May-December 2025).
• Cost of Sales: $2.6 million for Q4; $4.6 million for the full year.
• R&D Expenses: $31.7 million for Q4; $114.6 million for the full year, driven by ongoing clinical trials.
• SG&A Expenses: $24.4 million for Q4; $81.1 million for the full year, reflecting commercial launch activities.
• Non-GAAP Adjusted Net Loss: $39.8 million ($0.48 per share) for Q4; $163.1 million ($2.35 per share) for the full year.
• Cash Position: $205 million at the end of Q4, extending cash runway into the first half of 2027.

2. Strategic Updates and Business Highlights:

• FDA Approval: Achieved early approval for AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
• Market Adoption: Strong growth in prescribers, with nearly 300 active prescribers and over half of prescriptions coming from academic centers.
• Clinical Trials: Progress in RAMP 301 (confirmatory Phase III trial) and RAMP 205 (pancreatic cancer), with positive early results from the RAMP 201J study in Japan.
• Pipeline Development: Advancing VS-7375, a KRAS G12D inhibitor, with plans for accelerated approval pathways and combination studies.

3. Forward Guidance and Outlook:

• Expect LGSOC franchise to become self-sustaining in the second half of 2026.
• Continued focus on maximizing the commercial launch of AVMAPKI FAKZYNJA CO-PACK and generating data for VS-7375.
• Plans to share updates on clinical trials and expand educational efforts for healthcare providers and patients.

4. Bad News, Challenges, or Points of Concern:

• NCCN Guidelines: Recent guidelines did not expand recommendations for wild-type patients, which could limit treatment options for this cohort despite ongoing reimbursement success.
• Reimbursement Concerns: Some pushback from payers on off-label uses, particularly in brain and lung cancers, indicating potential hurdles in broader market access.
• Financial Losses: Increased net losses year-over-year, raising questions about long-term financial sustainability without additional funding.

5. Notable Q&A Insights:

• Management expressed disappointment regarding the NCCN decision but remains confident in ongoing reimbursement efforts for wild-type patients.
• Safety profile of VS-7375 appears favorable compared to earlier trials in China, with low rates of dose modifications and discontinuations.
• Future financing strategies will focus on non-dilutive options, with the belief that the LGSOC franchise will support operations without needing immediate fundraising.
• Plans to reengage with NCCN for future guideline updates based on upcoming trial data, particularly from RAMP 301.

This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, and challenges faced by Verastem Oncology as discussed during the earnings call.